HCL Technologies Grants Over 4.3 Million RSUs to Employees Under 2021 & 2024 Plans
HCL Technologies has granted 43,27,271 RSUs to 2,111 employees under its 2021 and 2024 plans. The grants vest between July 2027 and July 2029. Shares will be acquired from the secondary market, with no dilution. The exercise price is ₹2 per RSU.
The grant of RSUs is a routine part of employee compensation and stock option plans. The number of shares involved represents a small percentage of the total paid-up capital, and since shares are acquired from the secondary market, there is no dilution effect, limiting the impact.
The grant of RSUs is a standard employee compensation practice and does not inherently signal a positive or negative development for the company's financial performance or stock value.
HCL Technologies Limited has announced the grant of 43,27,271 Restricted Stock Units (RSUs) to eligible employees under its RSU Plan 2021 and RSU Plan 2024. This grant represents approximately 0.159% of the company's paid-up equity share capital as of the grant date.
The RSU Plan 2021 involves the grant of 2,04,784 RSUs to 9 employees, with a vesting date of July 31, 2027. The RSU Plan 2024 includes a larger grant of 41,22,487 RSUs to 2,102 employees, with vesting dates spread across July 31, 2027, June 30, 2028, July 31, 2028, June 30, 2029, and July 31, 2029.
Each RSU, upon vesting and exercise, entitles the holder to one fully paid-up equity share of the company. The shares for these RSUs will be acquired from the secondary market by a trust and then transferred to the employees, meaning no new shares will be issued by HCL Technologies. The exercise price for each RSU is ₹2, at par value. Additionally, 15,265 RSUs under the 2021 plan and 11,356 RSUs under the 2024 plan, previously approved, have been cancelled.
The company is re-submitting this intimation to the stock exchanges due to a technical glitch observed on the NSE's NEAPS system, ensuring the information is available on both BSE and NSE platforms. The Nomination and Remuneration Committee approved these grants on July 2, 2026, with the approval by circulation finalized on July 3, 2026.
What to do with a filing like this
HCL Technologies Limited filed this with the NSE as a statutory disclosure, categorised under designated person disclosures. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by HCL Technologies Limited. Read the original for the full detail.